T

Tatva Chintan Pharma Chem Limited

TATVA
Market snapshot · 2026-08-11 10:30 UTC

1,785.50

+₹9.90 (+0.56%)

MARKET CAP

₹4.18K Cr

STOCK P/E

81.2x

52W HIGH

₹1,838.10

52W LOW

₹976.40

BOOK VALUE

₹334.03

EPS

₹22.00

ROE

SECTOR

Materials

DEBT/EQUITY

15.40

VOLUME

39,439

P/B RATIO

5.35x

PEG RATIO

0.58

Sector

Materials

Themes

Specialty ChemicalsMukul Agrawal PortfolioGoldman Sachs Portfolio
D
Dividend
E
Earnings
₹1,788.20₹1,590.30₹1,392.41₹1,194.51₹996.61VolumeDEEEEAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Valuation Metrics

Trading 56.0% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.22). Confidence: 76%.

Live forward EPS implies next-12-month EPS of ₹40.87. Applying the stock's normalized valuation corridor produces a fair range of ₹1,806.05 to ₹2,524.54, with base value near ₹2,126.06 (+19.1% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Below normalized range

Forward EPS

₹40.87

Forward P/E

43.7x

Base Fair Value

₹2,126.06

Fair Range

₹1,806.05 - ₹2,524.54

Upside To Base

+19.1%

Estimate Source

Live forward EPS

Growth Estimate

+140.5%

P/E
Strongly Overvalued

5Y Average

70.60

Current

81.16

Overvalued

61.77

Undervalued

44.19

EV/EBITDA
Fair

5Y Average

34.01

Current

39.10

Overvalued

46.50

Undervalued

23.03

P/B
Strongly Overvalued

5Y Average

3.74

Current

5.35

Overvalued

4.30

Undervalued

3.18

Peers & Comparison

Sector: Materials · Theme: Specialty Chemicals

Specialty Chemicals Peers7 peers
Avg P/E: 56.5x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
ANUPAM RASAYAN INDIA LTD
ANURASSpecialty Chemicals
+27.5%7.2%
78.6x
Premium
+39% vs avg
+6.7%
NEOGEN CHEMICALS LIMITED
NEOGENSpecialty Chemicals
+34.0%3.8%
147.5x
Premium
+161% vs avg
+50.8%
SUPREME PETROCHEM LIMITED
SPLPETROSpecialty Chemicals
+23.7%8.5%
26.8x
Undervalued
-53% vs avg
-5.4%
GALAXY SURFACTANTS LTD
GALAXYSURFSpecialty Chemicals
+14.8%5.1%
27.1x
Undervalued
-52% vs avg
-14.4%
FINE ORGANIC IND. LTD.
FINEORGSpecialty Chemicals
+22.1%17.8%
37.5x
Undervalued
-34% vs avg
+5.6%
PRIVI SPECIALITY CHE LTD
PRIVISCLSpecialty Chemicals
+19.2%13.1%
41.7x
Undervalued
-26% vs avg
+50.0%
CLEAN SCIENCE & TECH LTD
CLEANSpecialty Chemicals
+10.5%23.7%
36.5x
Undervalued
-35% vs avg
-30.7%
WHY THESE PEERS

TATVA CHIN PHARM CHEM LTD trades at a premium (81.2x vs peer avg 56.5x), implying higher growth or quality expectations from the Specialty Chemicals cohort. Peers include ANUPAM RASAYAN INDIA LTD, NEOGEN CHEMICALS LIMITED, SUPREME PETROCHEM LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹139 CrDec 2025

Latest net profit

₹16 CrDec 2025

Latest EPS

₹6.84Dec 2025

Net margin

12.7%Dec 2025

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26-5.0%0.0%5.0%10.0%15.0%-50 Cr0.00 Cr50 Cr100 Cr150 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '260.00 Cr35 Cr70 Cr105 Cr140 Cr₹-3₹0₹3₹6₹9
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestProfitbefore taxTax & otherNet Profit0.00 Cr35 Cr70 Cr105 Cr140 Cr

Latest reported period: Dec 2025

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
20212022202320242025-180 Cr-90 Cr0.00 Cr90 Cr180 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales11910692.5786.0793.9393.8180.9684108109116139
Expenses10486.571.8373.7679.7386.1276.3778.3699.7494.1294.75112
Operating Profit12.8813.613.965.737.971.03-2.22-1.280.656.0912.0617.55
OPM %10.79%12.82%15.08%6.66%8.49%1.1%-2.74%-1.52%0.6%5.58%10.41%12.66%
Other Income0.781.020.761.214.531.420.810.041.31.370.791.73
Interest3.182.93.010.380.220.310.170.420.390.410.510.49
Depreciation2.536.016.786.586.236.666.816.927.268.979.059.07
Profit before tax10.4811.7211.716.5612.282.14-1.58-1.661.567.0512.3418.79
Tax %-45.9%29.61%29.97%29.12%32.82%29.44%11.39%25.9%30.13%27.23%27.55%14.95%
Net Profit15.298.258.24.658.251.51-1.4-1.231.095.138.9415.98
EPS in Rs7.293.723.631.993.520.64-0.47-0.500.472.193.826.84

All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.

Shareholding Pattern

HolderMar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters72.02%72.02%72.02%72.02%72.02%
FII3.30%3.26%3.40%4.17%3.81%
DII5.46%5.11%3.87%3.32%2.99%
Public16.92%17.47%18.29%17.91%18.31%
Others2.30%2.14%2.42%2.58%2.87%
Mar 2026
Promoters
FII
DII
Public
Others